Is Lyell Immunopharma Stock a Good Investment?
Lyell Immunopharma Investment Advice | LYEL |
- Examine Lyell Immunopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Lyell Immunopharma's leadership team and their track record. Good management can help Lyell Immunopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Lyell Immunopharma's business and its evolving consumer preferences.
- Compare Lyell Immunopharma's performance and market position to its competitors. Analyze how Lyell Immunopharma is positioned in terms of product offerings, innovation, and market share.
- Check if Lyell Immunopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Lyell Immunopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Lyell Immunopharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Lyell Immunopharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Lyell Immunopharma Stock
Researching Lyell Immunopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 14.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.48. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lyell Immunopharma has Price/Earnings To Growth (PEG) ratio of 0.68. The entity recorded a loss per share of 0.79. The firm had not issued any dividends in recent years.
To determine if Lyell Immunopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lyell Immunopharma's research are outlined below:
| Lyell Immunopharma generated a negative expected return over the last 90 days | |
| Lyell Immunopharma has high historical volatility and very poor performance | |
| Lyell Immunopharma has some characteristics of a very speculative penny stock | |
| Lyell Immunopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 130 K. Net Loss for the year was (234.63 M) with profit before overhead, payroll, taxes, and interest of 84.68 M. | |
| Lyell Immunopharma currently holds about 655.56 M in cash with (163.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lyell Immunopharma has a poor financial position based on the latest SEC disclosures | |
| Roughly 62.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Lyell Immunopharma Director Hans bishop resigns |
Lyell Immunopharma Quarterly Cost Of Revenue |
|
Lyell Immunopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lyell Immunopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lyell Immunopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Lyell Immunopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Lyell Immunopharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.205 | -0.18 | 0.025 | 12 | ||
2024-11-08 | 2024-09-30 | -0.2 | -0.17 | 0.03 | 15 | ||
2024-02-28 | 2023-12-31 | -0.23 | -0.2 | 0.03 | 13 | ||
2023-05-04 | 2023-03-31 | -0.28 | -0.23 | 0.05 | 17 | ||
2024-05-07 | 2024-03-31 | -0.21 | -0.15 | 0.06 | 28 | ||
2022-03-29 | 2021-12-31 | -0.28 | -0.35 | -0.07 | 25 | ||
2021-11-12 | 2021-09-30 | -0.27 | -0.2 | 0.07 | 25 | ||
2023-11-07 | 2023-09-30 | -0.25 | -0.17 | 0.08 | 32 |
Know Lyell Immunopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lyell Immunopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lyell Immunopharma backward and forwards among themselves. Lyell Immunopharma's institutional investor refers to the entity that pools money to purchase Lyell Immunopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sc China Holding Ltd | 2024-09-30 | 3 M | Mic Capital Management Uk Llp | 2024-09-30 | 1.7 M | Opaleye Management Inc | 2024-09-30 | 1.4 M | Northern Trust Corp | 2024-09-30 | 1.4 M | Balyasny Asset Management Llc | 2024-09-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.1 M | Fmr Inc | 2024-09-30 | 1 M | Td Asset Management Inc | 2024-09-30 | 1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 901.5 K | Mwg Management Ltd. | 2024-06-30 | 20.2 M | Orland Properties Ltd | 2024-06-30 | 15.1 M |
Lyell Immunopharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 257.02 M.Market Cap |
|
Lyell Immunopharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.35) | (0.36) | |
| Return On Assets | (0.31) | (0.33) | |
| Return On Equity | (0.36) | (0.38) |
Determining Lyell Immunopharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Lyell Immunopharma is a good buy. For example, gross profit margin measures Lyell Immunopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lyell Immunopharma's profitability and make more informed investment decisions.
Evaluate Lyell Immunopharma's management efficiency
Lyell Immunopharma has return on total asset (ROA) of (0.1912) % which means that it has lost $0.1912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3322) %, meaning that it created substantial loss on money invested by shareholders. Lyell Immunopharma's management efficiency ratios could be used to measure how well Lyell Immunopharma manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.33. The value of Return On Capital Employed is expected to slide to -0.36. At this time, Lyell Immunopharma's Total Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 1 B this year, although the value of Other Assets will most likely fall to about 4.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.61 | 2.30 | |
| Tangible Book Value Per Share | 2.61 | 2.30 | |
| Enterprise Value Over EBITDA | (1.78) | (1.87) | |
| Price Book Value Ratio | 0.74 | 0.71 | |
| Enterprise Value Multiple | (1.78) | (1.87) | |
| Price Fair Value | 0.74 | 0.71 | |
| Enterprise Value | 4.7 B | 4.5 B |
Lyell Immunopharma benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Beta (0.48) |
Basic technical analysis of Lyell Stock
As of the 29th of November, Lyell Immunopharma secures the Risk Adjusted Performance of (0.04), mean deviation of 4.8, and Standard Deviation of 6.92. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lyell Immunopharma, as well as the relationship between them. Please verify Lyell Immunopharma mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and kurtosis to decide if Lyell Immunopharma is priced some-what accurately, providing market reflects its recent price of 0.92 per share. Given that Lyell Immunopharma is a hitting penny stock territory we strongly suggest to closely look at its jensen alpha.Lyell Immunopharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lyell Immunopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lyell Immunopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lyell Immunopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lyell Immunopharma's Outstanding Corporate Bonds
Lyell Immunopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Lyell Immunopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Lyell bonds can be classified according to their maturity, which is the date when Lyell Immunopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| US55087PAB04 Corp BondUS55087PAB04 | View |
Understand Lyell Immunopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Lyell Immunopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 4.8 | |||
| Coefficient Of Variation | (1,488) | |||
| Standard Deviation | 6.92 | |||
| Variance | 47.93 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.89) | |||
| Total Risk Alpha | (1.52) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 36.92 | |||
| Value At Risk | (9.47) | |||
| Potential Upside | 13.39 | |||
| Skewness | 0.667 | |||
| Kurtosis | 1.25 |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 4.8 | |||
| Coefficient Of Variation | (1,488) | |||
| Standard Deviation | 6.92 | |||
| Variance | 47.93 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.89) | |||
| Total Risk Alpha | (1.52) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 36.92 | |||
| Value At Risk | (9.47) | |||
| Potential Upside | 13.39 | |||
| Skewness | 0.667 | |||
| Kurtosis | 1.25 |
Consider Lyell Immunopharma's intraday indicators
Lyell Immunopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lyell Immunopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Lyell Immunopharma time-series forecasting models is one of many Lyell Immunopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lyell Immunopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Lyell Stock media impact
Far too much social signal, news, headlines, and media speculation about Lyell Immunopharma that are available to investors today. That information is available publicly through Lyell media outlets and privately through word of mouth or via Lyell internal channels. However, regardless of the origin, that massive amount of Lyell data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lyell Immunopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lyell Immunopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lyell Immunopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lyell Immunopharma alpha.
Lyell Immunopharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Lyell Immunopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Lyell Immunopharma Corporate Management
| Elizabeth Homans | CEO Director | Profile | |
| Richard Goold | Chief Officer | Profile | |
| Stephen Hill | Chief Officer | Profile | |
| Crystal MD | Founder Advisor | Profile | |
| Charles Newton | Chief Officer | Profile | |
| Prof MD | Founder Advisor | Profile | |
| Nellie Dillery | Director Accounting | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Quarterly Revenue Growth 0.36 | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Lyell Immunopharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.